论文部分内容阅读
用差异ＰＣＲ方法检测了１３１例乳腺癌Ｃ－ｅｒｂＢ－２基因扩增，免疫组化法检测了１３１例乳腺癌Ｃ－ｅｒｂＢ－２和Ｃａｔｈｅｐｓｉｎ－Ｄ表达，并对其对乳腺癌的预后影响进行评价。Ｃ－ｅｒｂＢ２基因扩增阳性率为２９．０１％，与临床分期、病理类型、组织学分级和淋巴结转移状况无明显相关，与Ｃ－ｅｒｂＢ－２蛋白表达虽不完全吻合但呈高度相关。Ｃ－ｅｒｂＢ－２表达阳性率为３２．０６％，与临床分期、病理类型、组织学分级、淋巴结转移状况及瘤体大小未见明显相关，转移灶和原发灶表达一致。Ｃａｔｈｅｐ－ｓｉｎ－Ｄ表达阳性率为３２．０６％，与淋巴瘤结转移状况、Ｃ－ｅｒｂＢ－２表达及病理类型明显相关。单因素分析表明Ｃ－ｅｒｂＢ－２基因扩增、Ｃ－ｅｒｂＢ－２表达及Ｃａｔｈ－Ｄ表达对乳腺癌术后生存及无瘤生存影响显著，Ｃｏｘ模型多因素回归分析表明Ｃ－ｅｒｂＢ－２表达是乳腺癌一独立预后指标。联合应用Ｃ－ｅｒｂＢ－２和Ｃａｔｈ－Ｄ表达检测更有助于早期病例和淋巴结转移阴性病例中高危患者的筛选。
The C-erbB-2 gene amplification in 131 cases of breast cancer was detected by differential PCR. The expression of C-erbB-2 and Cathepsin-D in 131 cases of breast cancer was detected by immunohistochemistry and the prognosis of breast cancer was evaluated. Evaluation. The positive rate of C-erbB2 gene amplification was 29.01%, which was not significantly correlated with clinical stage, pathological type, histological grade, and lymph node metastasis. Although it was not completely consistent with C-erbB-2 protein expression, it was highly correlated. The positive rate of C-erbB-2 expression was 32.06%. There was no significant correlation with clinical stage, pathological type, histological grade, lymph node metastasis, and tumor size. The expression of metastatic and primary tumors was consistent. The positive rate of catep-sin-D expression was 32.06%, which was significantly correlated with the lymph node metastasis status, C-erbB-2 expression and pathological type. Univariate analysis showed that C-erbB-2 gene amplification, C-erbB-2 expression, and Cath-D expression had significant effects on survival and tumor-free survival after breast cancer surgery. Multivariate regression analysis of Cox model showed that C-erbB-2 was expressed. It is an independent prognostic indicator of breast cancer. Combined use of C-erbB-2 and Cath-D expression tests is more helpful for the screening of high-risk patients in early cases and negative lymph node metastases.